In order to expand its solid tumour portfolio, AbbVie has agreed to acquire ImmunoGen for US$31.26 per share in cash, representing a total equity value of approximately US$10.1 B. With the takeover, AbbVie will gain access to ImmunoGen’s marketed cancer therapy Elahere® (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved in the US for platinum-resistant ovarian cancer (PROC), as well as its pipeline of ADC programmes. The deal marks yet another move by a big pharma within the ADC space, as oncology drug makers look to invest in these promising modalities.